Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share (PRLD)

Q: What does CUSIP 74065P101 represent in this 13F holders report?

CUSIP 74065P101 is the security identifier for PRLD - Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share used to aggregate holder disclosures.

Q: How many institutions held PRLD - Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share in Q1 2021?

60 institutional investors reported PRLD - Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share for Q1 2021. Use the holders table for investor-level position and value details.

CUSIP: 74065P101

Q1 2021 13F Holders as of 31 Mar 2021

Type / Class: Equity / Common Stock, $0.0001 par value per share
Shares outstanding: 66,421,297
Total 13F shares: 32,543,650
Share change: -2,108,240
Total reported value: $1,410,113,760
Price per share: $43.33
Number of holders: 60
Value change: -$96,898,538
Number of buys: 46
Number of sells: 16

Quarterly Holders Quick Answers

What is CUSIP 74065P101?
CUSIP 74065P101 identifies PRLD - Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q2 2021
Previous quarter: Q4 2020

Recent filing periods for CUSIP 74065P101:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of PRLD - Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
ORBIMED ADVISORS LLC	13F	Company	23%	15,594,877	$1,115,813,000	—	31 Dec 2020	13F
BAKER BROS. ADVISORS LP	13F	Company	15%	10,118,636	$723,988,000	—	31 Dec 2020	13F
FMR LLC	13F	Company	6.3%	4,209,963	$296,295,000	—	31 Dec 2020	13F
HHLR ADVISORS, LTD.	13F	Company	1.1%	750,000	$53,663,000	—	31 Dec 2020	13F
VANGUARD GROUP INC	13F	Company	0.99%	659,845	$47,212,000	—	31 Dec 2020	13F
BlackRock Finance, Inc.	13F	Company	0.96%	637,133	$45,587,000	—	31 Dec 2020	13F
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	13F	Company	0.78%	516,029	$36,921,875	—	31 Dec 2020	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	0.58%	387,680	$27,739,000	—	31 Dec 2020	13F
Rock Springs Capital Management LP	13F	Company	0.54%	360,363	$25,784,000	—	31 Dec 2020	13F
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	13F	Company	0.43%	284,187	$20,334,000	—	31 Dec 2020	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.29%	191,628	$13,710,000	—	31 Dec 2020	13F
FEDERATED HERMES, INC.	13F	Company	0.23%	150,000	$10,733,000	—	31 Dec 2020	13F
STATE STREET CORP	13F	Company	0.21%	142,333	$10,184,000	—	31 Dec 2020	13F
NORTHERN TRUST CORP	13F	Company	0.17%	115,023	$8,229,000	—	31 Dec 2020	13F
SUVRETTA CAPITAL MANAGEMENT, LLC	13F	Company	0.17%	111,065	$7,947,000	—	31 Dec 2020	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.1%	68,568	$4,907,000	—	31 Dec 2020	13F
CAAS CAPITAL MANAGEMENT LP	13F	Company	0.08%	50,000	$3,578,000	—	31 Dec 2020	13F
Nuveen Asset Management, LLC	13F	Company	0.05%	34,722	$2,484,000	—	31 Dec 2020	13F
Bank of New York Mellon Corp	13F	Company	0.05%	30,973	$2,216,000	—	31 Dec 2020	13F
MORGAN STANLEY	13F	Company	0.04%	27,128	$1,941,000	—	31 Dec 2020	13F
JPMORGAN CHASE & CO	13F	Company	0.04%	24,496	$1,753,000	—	31 Dec 2020	13F
TD ASSET MANAGEMENT INC	13F	Company	0.03%	22,509	$1,611,000	—	31 Dec 2020	13F
Squarepoint Ops LLC	13F	Company	0.03%	20,726	$1,483,000	—	31 Dec 2020	13F
NORGES BANK	13F	Company	0.03%	20,000	$1,431,000	—	31 Dec 2020	13F
CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM	13F	Company	0.03%	19,290	$1,380,000	—	31 Dec 2020	13F
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	13F	Company	0.02%	13,888	$994,000	—	31 Dec 2020	13F
RHUMBLINE ADVISERS	13F	Company	0.01%	9,546	$683,000	—	31 Dec 2020	13F
ALLIANCEBERNSTEIN L.P.	13F	Company	0.01%	8,600	$615,000	—	31 Dec 2020	13F
ARS Investment Partners, LLC	13F	Company	0.01%	7,400	$529,000	—	31 Dec 2020	13F
NEW YORK STATE COMMON RETIREMENT FUND	13F	Company	0.01%	7,200	$515,000	—	31 Dec 2020	13F
DEUTSCHE BANK AG\	13F	Company	0.01%	6,750	$483,000	—	31 Dec 2020	13F
AMERICAN INTERNATIONAL GROUP, INC.	13F	Company	0.01%	5,338	$382,000	—	31 Dec 2020	13F
MANUFACTURERS LIFE INSURANCE COMPANY, THE	13F	Company	0.01%	5,289	$378,000	—	31 Dec 2020	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.01%	4,806	$344,000	—	31 Dec 2020	13F
PERSONAL CFO SOLUTIONS, LLC	13F	Company	0.01%	4,500	$322,000	—	31 Dec 2020	13F
MetLife Investment Management, LLC	13F	Company	0.01%	4,119	$294,714	—	31 Dec 2020	13F
VOYA INVESTMENT MANAGEMENT LLC	13F	Company	0.01%	3,665	$262,000	—	31 Dec 2020	13F
Old Well Partners, LLC	13F	Company	0.01%	3,450	$247,000	—	31 Dec 2020	13F
Athanor Capital, LP	13F	Company	0.01%	3,374	$241,000	—	31 Dec 2020	13F
METROPOLITAN LIFE INSURANCE CO/NY	13F	Company	0%	2,879	$205,992	—	31 Dec 2020	13F
ROYAL BANK OF CANADA	13F	Company	0%	2,831	$203,000	—	31 Dec 2020	13F
UBS Group AG	13F	Company	0%	2,581	$185,000	—	31 Dec 2020	13F
STRS OHIO	13F	Company	0%	2,200	$157,000	—	31 Dec 2020	13F
CITIGROUP INC	13F	Company	0%	1,731	$124,000	—	31 Dec 2020	13F
BANK OF MONTREAL /CAN/	13F	Company	0%	1,434	$98,000	—	31 Dec 2020	13F
Legal & General Group Plc	13F	Company	0%	1,004	$72,000	—	31 Dec 2020	13F
Ameritas Investment Partners, Inc.	13F	Company	0%	769	$55,000	—	31 Dec 2020	13F
BANK OF AMERICA CORP /DE/	13F	Company	0%	490	$35,000	—	31 Dec 2020	13F
Jacobi Capital Management LLC	13F	Company	0%	250	$18,000	—	31 Dec 2020	13F
Tower Research Capital LLC (TRC)	13F	Company	0%	205	$15,000	—	31 Dec 2020	13F

Institutional Holders of Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share (PRLD) as of Q1 2021

As of 31 Mar 2021, Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share (PRLD) was held by 60 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 32,543,650 shares. The largest 10 holders included BAKER BROS. ADVISORS LP, ORBIMED ADVISORS LLC, FMR LLC, STATE STREET CORP, VANGUARD GROUP INC, BlackRock Inc., UBS ASSET MANAGEMENT AMERICAS INC, HILLHOUSE CAPITAL ADVISORS, LTD., PRICE T ROWE ASSOCIATES INC /MD/, and Rock Springs Capital Management LP. This page lists 60 institutional shareholders reporting positions in this security for the Q1 2021 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2021 vs Q4 2020 Across Filers

Q4 2020 holders

Q1 2021 holders

Holder diff

Investor	Q4 2020 Shares	Q1 2021 Shares	Share Diff	Share Chg %	Q4 2020 Value $	Q1 2021 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.